{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"vTv Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"VTVT"},"Address":{"label":"Address","value":"3980 PREMIER DRIVE,SUITE 310, HIGH POINT, North Carolina, 27265, United States"},"Phone":{"label":"Phone","value":"+1 336 841-0300"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders."},"CompanyUrl":{"label":"Company Url","value":"https://www.vtvtherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Carmen Valcarce","title":"Chief Scientific Officer & Executive VP"},{"name":"Paul Jai Sekhri","title":"Chairman, President & Chief Executive Officer"},{"name":"Thomas Strack","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}